Superstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being unprofitable, the company has a strong balance sheet with $809.3 million in cash and runway into late 2028.

A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350 on April 6, 2026, representing 6.76% of her holdings. The sale aligns with her historical selling patterns and appears to be income supplementation rather than a loss of confidence. The company has shown positive momentum with encouraging clinical trial results for VIR-5500 and a significant partnership deal with Astellas Pharma worth $315 million.

U.S. stock futures rose on Tuesday following Monday's sell-off triggered by AI-related economic concerns and a viral 'Global Intelligence Crisis' report. Market sentiment remains cautious amid Trump's tariff threats and geopolitical tensions. Key movers include Keysight Technologies surging 16% on strong earnings, Vir Biotechnology jumping 63% on revenue beat, and Whirlpool plunging 7.46% after announcing an $800 million capital raise.

Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.

Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.

GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.

Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.

Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $71.4, a high estimate of $110.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 614.0% from the previous average price target of $10.00. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Vir Biotechnology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $12.00 $10.00 Joseph Stringer Needham Maintains Buy $15.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.com

Across the recent three months, 6 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 2 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.17, a high estimate of $110.00, and a low estimate of $10.00. This current average has increased by 76.43% from the previous average price target of $34.67. Breaking Down Analyst Ratings: A Detailed Examination In examining recent analyst actions, we gain insights into how financial experts perceive Vir Biotechnology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $12.00 $10.00 Joseph Stringer Needham Maintains Buy $15.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $10.00 $9.00 Patrick Trucchio HC Wainwright & Co. Raises Buy $110.00 $85.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.